


**Product Name** : TAS6417  
**Cat. No.** : PC-63499  
**CAS No.** : 1661854-97-2  
**Molecular Formula** : C<sub>23</sub>H<sub>20</sub>N<sub>6</sub>O  
**Molecular Weight** : 396.454  
**Target** : EGFR  
**Solubility** : 10 mM in DMSO



### Biological Activity

Zipalertinib (TAS6417, CLN-081) is a novel potent, selective inhibitor of **EGFR exon 20 insertion mutations** with IC<sub>50</sub> of 1.1-8.0 nM, >100-fold selectivity over WT EGFR.

Zipalertinib (TAS6417) fits into the ATP-binding site of the EGFR hinge region.

Zipalertinib (TAS6417) inhibits EGFR phosphorylation and downstream molecules in NSCLC cell lines expressing EGFR exon 20 insertions (IC<sub>50</sub>=20-100 nM), resulting in caspase activation.

Zipalertinib (TAS6417) inhibits the proliferation of Ba/F3 cells driven by various EGFR exon 20 insertion mutations with IC<sub>50</sub> of 5.05-150 nM.

Zipalertinib (TAS6417) causes persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models.

### References

Hasako S, et al. *Mol Cancer Ther.* 2018 May 10. pii: molcanther.1206.2017.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com